Literature DB >> 15293286

Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.

Sean J Pittock1, Robyn L McClelland, William T Mayr, Neal W Jorgensen, Brian G Weinshenker, John Noseworthy, Moses Rodriguez.   

Abstract

In 2001, we followed up all patients from the 1991 Olmsted County Multiple Sclerosis (MS) prevalence cohort. We found that the longer the duration of MS and the lower the disability, the more likely a patient is to remain stable and not progress. This is particularly powerful for patients with benign MS with Expanded Disability Status Scale score of 2 or lower for 10 years or longer who have a greater than 90% chance of remaining stable. This is important because these patients represent 17% of the entire prevalence cohort. These data should assist in the shared therapeutic decision-making process of whether to start immunomodulatory medications. Copyright 2004 American Neurological Association

Entities:  

Mesh:

Year:  2004        PMID: 15293286     DOI: 10.1002/ana.20197

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  51 in total

Review 1.  Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.

Authors:  Annette Langer-Gould; Lawrence Steinman
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Overcoming the clinical-MR imaging paradox of multiple sclerosis: MR imaging data assessed with a random forest approach.

Authors:  K Kacar; M A Rocca; M Copetti; S Sala; S Mesaros; T Stosic Opincal; D Caputo; M Absinta; J Drulovic; V S Kostic; G Comi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2011-11-11       Impact factor: 3.825

Review 3.  The radiologically isolated syndrome: take action when the unexpected is uncovered?

Authors:  Johann Sellner; Lucas Schirmer; Bernhard Hemmer; Mark Mühlau
Journal:  J Neurol       Date:  2010-05-26       Impact factor: 4.849

Review 4.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

5.  Depression in multiple sclerosis: a longitudinal analysis.

Authors:  Claudia C Beal; Alexa K Stuifbergen; Adama Brown
Journal:  Arch Psychiatr Nurs       Date:  2007-08       Impact factor: 2.218

6.  Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features.

Authors:  Ichiro Nakashima; Toshiyuki Fukazawa; Kohei Ota; Chiyoko Nohara; Yoko Warabi; Takashi Ohashi; Isabelle Miyazawa; Kazuo Fujihara; Yasuto Itoyama
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

Review 7.  Pharmacological treatment of early multiple sclerosis.

Authors:  Olaf Stüve; Jeffrey L Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.

Authors:  Lutz Achtnichts; Oded Gonen; Daniel J Rigotti; James S Babb; Yvonne Naegelin; Iris-Katharina Penner; Kerstin Bendfeldt; Jochen Hirsch; Michael Amann; Ludwig Kappos; Achim Gass
Journal:  Eur J Radiol       Date:  2013-09-04       Impact factor: 3.528

9.  Allelic variation in the Tyk2 and EGF genes as potential genetic determinants of CNS repair.

Authors:  Allan J Bieber; Kanitta Suwansrinon; Jason Kerkvliet; Weidong Zhang; Larry R Pease; Moses Rodriguez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

10.  Disability in multiple sclerosis: a reference for patients and clinicians.

Authors:  Ilya Kister; Eric Chamot; Amber R Salter; Gary R Cutter; Tamar E Bacon; Joseph Herbert
Journal:  Neurology       Date:  2013-02-20       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.